The Covid-19 vaccine developed by Moderna, which is in its Phase 3 of its trials, has been found to be effective against the new variants of the virus emerging from the U.K. and South Africa, according to a research study published by the company. However, the study also notes that its efficacy against the variant from South Africa appears to be less than that from the U.K.
For this reason, Moderna has announced that it will develop booster shots to increase its vaccine’s effectiveness, especially against the South African variant. It is also working on another booster shot aimed at fighting all new variants broadly.
However, the company says that the new booster shots are more of a precaution as its authorised two-shot regimen offers substantial protection against new and old variants of the Covid-19 virus already.
For this reason, Moderna has announced that it will develop booster shots to increase its vaccine’s effectiveness, especially against the South African variant. It is also working on another booster shot aimed at fighting all new variants broadly.
However, the company says that the new booster shots are more of a precaution as its authorised two-shot regimen offers substantial protection against new and old variants of the Covid-19 virus already.